Prescribing information

 

   

Start ENTRESTO® today to help your chronic HFrEF patients feel better and improve their lives vs ACEi (enalapril)1,2

Most patients with heart failure report limitations in their daily activities due to physical symptoms such as dyspnoea, fatigue, oedema, sleeping difficulties and chest pain.
 

Starting ENTRESTO can lead to substantial improvements in social and physical activities comparable to feeling 9 YEARS YOUNGER vs ACEi (enalapril):*1

Image of 2 people, representing sexual relationship

Sexual relationships

Image of a person walking with a suitcase, representing hobbies and recreation

Hobbies & recreation

Image of a person mopping, representing household chores

Household chores

Image of a spade and a plant, representing gardening

Gardening

ENTRESTO improves how patients feel vs ACEi (enalapril)†2

 

Infographic representing Entresto improves how patients feel vs ACEi (enalapril). 3 x greater improvement in HRQoL as measured by KCCQ overall summary score was experienced by patients taking Entresto.

greater improvement in HRQoL as measured by KCCQ overall summary score was experienced by patients taking ENTRESTO§2

 

Infographic representing Entresto improves how patients feel vs ACEi (enalapril). Long lasting: HRQoL improvements when taking Entresto vs enalapril, detectable by 4 months after randomisation and sustained throughout 36 months.

HRQoL improvements when taking ENTRESTO vs enalapril, detectable by 4 months after randomisation and sustained throughout 36 months2

Starting ENTRESTO first-line can add up to 2 years to patients’ lives and life to their years1,2,4

 

Do you have routine reviews with patients over the phone or a virtual call?

 

Download the HFSN Virtual Consultations Infographics for practical advice on seeing HF patients in the virtual setting

down pointing arrow icon

 

See how guidelines support ENTRESTO as a first-line treatment option in HFrEF5–8

down pointing arrow icon

 

 

ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.9

* As measured by an analysis model that incorporated age and treatment effect. This analysis model was included in a secondary analysis of PARADIGM-HF that examined the effect of ENTRESTO on components of the physical and social limitation section of the KCCQ at 8 months, and longitudinally over 36 months. Patients in the ENTRESTO group had significantly better adjusted change scores in 7 out of 10 physical and social activities vs the enalapril group. The largest improvements over enalapril were in household chores (adjusted change score difference, 2.35 [95% CI, 1.19⁠–⁠3.50], P<0.001) and sexual relationships (adjusted change score difference, 2.72 [95% CI: 0.97–4.46], P=0.002); both persisted through 36 months (overall change score difference, 1.69 [95% CI: 0.78–2.60], P<0.001; and 2.36 [95% CI: 1.01–3.71], P=0.001, respectively).1 PARADIGM-HF was a multinational, randomised, double-blind trial comparing ENTRESTO to enalapril in 8,442 symptomatic (NYHA Class II-IV) HFrEF patients (LVEF ≤40%, amended later to ≤35%). For the primary endpoint, composite of CV death or first HF hospitalisation, ENTRESTO was superior to enalapril (P<0.0001). The median follow-up duration was 27 months.10
Post hoc analysis of PARADIGM-HF that examined the changes in KCCQ scores at randomisation, Month 4, Month 8, Month 12, and annually thereafter through final visit. 91% of patients enrolled in PARADIGM-HF (n=7,623/8,399) completed the KCCQ at randomisation, with complete data at 8 months for 6,881 patients (90% of baseline). At Month 8, the ENTRESTO group noted improvements in both KCCQ clinical summary score (+0.64 vs -0.29; P=0.008) and KCCQ overall summary score (+1.13 vs -0.14; P<0.001) in comparison to the enalapril group, as well as a significantly smaller proportion of patients with deterioration (≤5 points decrease) of both KCCQ scores (27% vs 31%; P=0.01). Adjusted change scores demonstrated consistent improvements in ENTRESTO vs enalapril through 36 months. Patients who died or did not complete the 8-month KCCQ score were excluded from the principal analysis.2
‡ KCCQ is a self-administered, health-related, QoL measure for HF patients that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and QoL on a scale of 0–100, with higher scores indicating fewer symptoms and physical limitations associated with HF. 7,618 of 8,399 patients from the PARADIGM-HF trial completed the initial KCCQ assessment.2
§ LSM estimation (SE) ENTRESTO vs enalapril: 0.80 (20) vs -0.39 (-0.20). LSM estimates (SE) difference: 1.19 (0.28), P<0.001.2

ACEi, angiotensin-converting enzyme inhibitor; CI, confidence interval; CV, cardiovascular; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFSN, Heart Failure Specialist Nurse; HRQoL, health-related quality of life; KCCQ, Kansas City Cardiomyopathy Questionnaire; LSM, least squares mean; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; QoL, quality of life; SE, standard error.

References:

  1. Chandra A, et al. JAMA Cardiol 2018;3(6):498–505.
  2. Lewis EF, et al. Circ Heart Fail 2017;10(8):e003430.
  3. Heo S, et al. Heart Lung 2009;38(2):100–108.
  4. Claggett B, et al. N Engl J Med 2015;373(23):2289–2290.
  5. CaReMe UK HF algorithm. Available at: https://www.britishcardiovascularsociety.org/__data/assets/powerpoint_do.... (Accessed September 2021).
  6. Maddox TM, et al. J Am Coll Cardiol 2021;77(6):772–810.
  7. Welsh HF Expert Reference Group 2021. HF in Wales in 2021 – a Parallel Approach.
  8. Heart Failure Hub Scotland guidelines. Available at: https://www.heartfailurehubscotland.co.uk/wp-content/uploads/2020/03/NHS.... (Accessed September 2021).
  9. ENTRESTO Summary of Product Characteristics. Electronic medicines compendium website, UK. Available at: https://www.medicines.org.uk/emc/product/7751/smpc. (Accessed September 2021).
  10. McMurray JJ, et al. N Engl J Med 2014;371:993–1004.
Rate this content: 
No votes yet
UK | October 2021 | 145891
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]